Influenza vaccine - aVaxziPen
Latest Information Update: 19 Oct 2023
At a glance
- Originator Enesi Pharma
- Developer aVaxziPen
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Influenza virus infections
Most Recent Events
- 19 Oct 2021 Enesi Pharma enters an agreement with National Institute of Allergy and Infectious Diseases to evaluate influenza vaccine
- 19 Oct 2021 Enesi Pharma and National Institute of Allergy and Infectious Diseases plans additional preclinical trial for Influenza vaccine, in Q4 2021
- 04 May 2021 Preclinical trials in Influenza virus infections (Prevention) in United Kingdom (Transdermal)